Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Gascoyne on Predictive Biomarker Research in Lymphomas

April 8th 2015

Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.

ASH Report Carves Out a New Role for Hematologists

April 3rd 2015

The American Society of Hematology is calling for the creation of a new clinical hematology specialty that would be based in a medical center or health system and would focus primarily on patients with benign blood disorders, while also helping to manage genomic testing and pathways-centered care.

FDA Approves New Oral Formulation of Deferasirox

March 31st 2015

The FDA has granted an accelerated approval to an oral formulation of deferasirox (Jadenu) for the treatment of patients aged 2 and older with chronic iron overload due to multiple blood transfusions.

MCL Patients Progressing on Ibrutinib Respond Poorly to Salvage Therapy

March 30th 2015

Patients with mantle cell lymphoma who develop ibrutinib resistance are unlikely to respond favorably to salvage chemotherapy.

On the Brink of Change

March 26th 2015

The profound changes under way in the treatment of leukemia were among the highlights captured in our coverage of the 19th Annual International Congress on Hematologic Malignancies:® Focus on Leukemias, Lymphomas, and Myeloma.

Dr. Bijal Shah on Bortezomib's Impact on Treatment of MCL

March 24th 2015

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Molecular Biology and Immunology Discoveries Drive Novel Strategies for Lymphoma

March 22nd 2015

Research and development in lymphomas are proliferating at such an accelerated pace that the promise of biomarker-driven targeted therapies is moving closer toward reality.

Dr. Komrokji on MDS Risk Factors and Preventative Measures

March 6th 2015

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the risk factors of developing myelodysplastic syndromes (MDS) and any preventative measures.

Carfilzomib Doubles PFS Over Bortezomib in Phase III Multiple Myeloma Trial

March 2nd 2015

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

Dr. Horwitz on the Challenges With T-Cell Lymphoma

February 25th 2015

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the challenges oncologists face with T-cell lymphoma.

Dr. Sotomayor on Precision Medicine for the Prevention of Cancer

February 23rd 2015

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

Molecular Analysis Should Guide Treatment Individualization in AML

February 23rd 2015

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

New Approaches Emerge for Treating ALL, Yet Challenges Remain

February 23rd 2015

The treatment landscape for acute lymphoblastic leukemia (ALL) is changing, pointing to promising new approaches clinicians can use in practice.

Novel Therapies in Hodgkin Lymphoma Coming to Clinics

February 21st 2015

Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

Dr. Michael Mauro on Treatment Discontinuation for CML

February 20th 2015

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

February 20th 2015

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

PD-1 Researchers Excited About Prospects for Checkpoint Strategy in Hodgkin Lymphoma

February 8th 2015

Amid continuing excitement over the potential for PD-1 pathway immune checkpoint blockade strategies in anticancer therapies, research presented at the 2014 American Society of Hematology (ASH) Annual Meeting helped established a foundation for the use of anti- PD-1/PD-L1 agents in hematologic malignancies.

Positive Interim Analysis Halts Phase III Obinutuzumab iNHL Trial

February 4th 2015

A phase III study of obinutuzumab in indolent non-Hodgkin lymphoma has been stopped early after a positive interim analysis.

JAK2 Mutations and JAK Inhibitors in the Management of Myeloproliferative Neoplasms

January 31st 2015

The Philadelphia chromosomeâ€“negative myeloproliferative neoplasms (MPNs) are clonal disorders characterized by common mutations, but with distinct clinical features, treatment considerations, and prognostic outlooks.

Dr. Brentjens on CAR T-Cell Therapy Challenges

January 30th 2015

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.